"Uridine Monophosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.
| Descriptor ID |
D014542
|
| MeSH Number(s) |
D03.383.742.686.850.877 D13.695.740.850.877 D13.695.827.919.877
|
| Concept/Terms |
Uridine Monophosphate- Uridine Monophosphate
- Monophosphate, Uridine
- Uridine 5'-Monophosphate
- 5'-Monophosphate, Uridine
- Uridine 5' Monophosphate
- Uridylic Acid
- Acid, Uridylic
- Uridylic Acids
- Acids, Uridylic
- UMP
|
Below are MeSH descriptors whose meaning is more general than "Uridine Monophosphate".
Below are MeSH descriptors whose meaning is more specific than "Uridine Monophosphate".
This graph shows the total number of publications written about "Uridine Monophosphate" by people in this website by year, and whether "Uridine Monophosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 5 | 6 | 11 |
| 2018 | 12 | 1 | 13 |
| 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Uridine Monophosphate" by people in Profiles.
-
Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2019 11; 69(5):595-598.
-
Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. Saudi J Gastroenterol. 2019 Jan-Feb; 25(1):55-60.
-
Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis. Hepatology. 2018 12; 68(6):2434-2437.
-
[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents]. An Pediatr (Engl Ed). 2019 Mar; 90(3):141-147.
-
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother. 2018 08 01; 73(8):2112-2119.
-
Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018 09; 38(9):1552-1561.
-
Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol. 2018 11; 113(11):1639-1648.
-
Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018 07; 48(1):35-43.
-
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. J Infect. 2018 06; 76(6):536-542.
-
Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase. Bioorg Med Chem Lett. 2018 07 15; 28(13):2324-2327.